Overcoming the Roadblocks to Cardiac Cell Therapy Using Tissue Engineering

Journal of the American College of Cardiology

Volumn 70, Issue 6, 2017, Pages 766-775

  Yanamandala, Mounica ^a   Zhu, Wuqiang ^b   Garry, Daniel J ^c   Kamp, Timothy J ^d   Hare, Joshua M ^e   Jun, Ho wook ^b   Yoon, Young sup ^f   Bursac, Nenad ^g   Prabhu, Sumanth D ^h   Dorn, Gerald W ⁱ   Bolli, Roberto ^j   Kitsis, Richard N ^a   Zhang, Jianyi ^b  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b 803 Shelby Interdisciplinary Biomedical Research Building   (United States)

^c UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^e UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^f EMORY UNIVERSITY   (United States)

^g USA   (United States)

^h University of Alabama at Birmingham   (United States)

ⁱ WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j University of Louisville School of Medicine   (United States)

more..

Author keywords

biocompatible materials; heart failure; myocardial infarction; myocardium; stem cells

Indexed keywords

ARRHYTHMOGENESIS; BIOENERGY; CARDIAC MUSCLE CELL; CELL FUNCTION; CELL REGENERATION; CELL STRUCTURE; CELL SURVIVAL; CONVALESCENCE; GENETIC ENGINEERING; GRAFT FAILURE; GRAFT RECIPIENT; HEART FUNCTION; HEART INFARCTION; HEART MUSCLE CONTRACTILITY; HEART MUSCLE INJURY; HEART TISSUE; HUMAN; IMMUNOGENICITY; IMMUNOMODULATION; NONHUMAN; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; REVIEW; STEM CELL TRANSPLANTATION; TISSUE ENGINEERING; TISSUE REGENERATION; BIOLOGICAL THERAPY; HEART DISEASES; PROCEDURES;

CELL- AND TISSUE-BASED THERAPY; HEART DISEASES; HUMANS; TISSUE ENGINEERING;

EID: 85028597123     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2017.06.012     Document Type: Review

References (86)

1. Nguyen, P.K., Rhee, J.W., Wu, J.C., Adult stem cell therapy and heart failure, 2000 to 2016: a systematic review. JAMA Cardiol 1 (2016), 831–841.
2. Lalit, P.A., Salick, M.R., Nelson, D.O., et al. Lineage reprogramming of fibroblasts into proliferative induced cardiac progenitor cells by defined factors. Cell Stem Cell 18 (2016), 354–367.
3. Zhang, Y., Cao, N., Huang, Y., et al. Expandable cardiovascular progenitor cells reprogrammed from fibroblasts. Cell Stem Cell 18 (2016), 368–381.
4. Jackman, C.P., Carlson, A.L., Bursac, N., Dynamic culture yields engineered myocardium with near-adult functional output. Biomaterials 111 (2016), 66–79.
5. Jackman, C.P., Shadrin, I.Y., Carlson, A.L., Bursac, N., Human cardiac tissue engineering: from pluripotent stem cells to heart repair. Curr Opin Chem Eng 7 (2015), 57–64.
6. Zhang, D., Shadrin, I.Y., Lam, J., Xian, H.Q., Snodgrass, H.R., Bursac, N., Tissue-engineered cardiac patch for advanced functional maturation of human ESC-derived cardiomyocytes. Biomaterials 34 (2013), 5813–5820.
7. Zhang, J., Klos, M., Wilson, G.F., et al. Extracellular matrix promotes highly efficient cardiac differentiation of human pluripotent stem cells: the matrix sandwich method. Circ Res 111 (2012), 1125–1136.
8. Lian, X., Hsiao, C., Wilson, G., et al. Robust cardiomyocyte differentiation from human pluripotent stem cells via temporal modulation of canonical Wnt signaling. Proc Natl Acad Sci U S A 109 (2012), E1848–E1857.
9. Yang, L., Geng, Z., Nickel, T., et al. Differentiation of human induced-pluripotent stem cells into smooth-muscle cells: two novel protocols. PLoS One, 11, 2016, e0147155.
10. Ye, L., Zhang, S., Greder, L., et al. Effective cardiac myocyte differentiation of human induced pluripotent stem cells requires VEGF. PLoS One, 8, 2013, e53764.
11. Zhang, S., Dutton, J.R., Su, L., Zhang, J., Ye, L., The influence of a spatiotemporal 3D environment on endothelial cell differentiation of human induced pluripotent stem cells. Biomaterials 35 (2014), 3786–3793.
12. Campagnolo, P., Tsai, T.N., Hong, X., et al. c-Kit+ progenitors generate vascular cells for tissue-engineered grafts through modulation of the Wnt/Klf4 pathway. Biomaterials 60 (2015), 53–61.
13. Dorn, G.W. II, Vega, R.B., Kelly, D.P., Mitochondrial biogenesis and dynamics in the developing and diseased heart. Genes Dev 29 (2015), 1981–1991.
14. Dorn, G.W. II, Kitsis, R.N., The mitochondrial dynamism-mitophagy-cell death interactome: multiple roles performed by members of a mitochondrial molecular ensemble. Circ Res 116 (2015), 167–182.
15. Chung, S., Dzeja, P.P., Faustino, R.S., Perez-Terzic, C., Behfar, A., Terzic, A., Mitochondrial oxidative metabolism is required for the cardiac differentiation of stem cells. Nat Clin Pract Cardiovasc Med 4:Suppl 1 (2007), S60–S67.
16. Kasahara, A., Cipolat, S., Chen, Y., Dorn, G.W. II, Scorrano, L., Mitochondrial fusion directs cardiomyocyte differentiation via calcineurin and Notch signaling. Science 342 (2013), 734–737.
17. Wendel, J.S., Ye, L., Zhang, P., Tranquillo, R.T., Zhang, J.J., Functional consequences of a tissue-engineered myocardial patch for cardiac repair in a rat infarct model. Tissue Eng Part A 20 (2014), 1325–1335.
18. Ruwhof, C., van Wamel, A.E., Egas, J.M., van der Laarse, A., Cyclic stretch induces the release of growth promoting factors from cultured neonatal cardiomyocytes and cardiac fibroblasts. Mol Cell Biochem 208 (2000), 89–98.
19. van Wamel, A.J., Ruwhof, C., van der Valk-Kokshoorn, L.J., Schrier, P.I., van der Laarse, A., Stretch-induced paracrine hypertrophic stimuli increase TGF-beta1 expression in cardiomyocytes. Mol Cell Biochem 236 (2002), 147–153.
20. Masumoto, H., Matsuo, T., Yamamizu, K., et al. Pluripotent stem cell-engineered cell sheets reassembled with defined cardiovascular populations ameliorate reduction in infarct heart function through cardiomyocyte-mediated neovascularization. Stem Cells 30 (2012), 1196–1205.
21. Martin, C.M., Meeson, A.P., Robertson, S.M., et al. Persistent expression of the ATP-binding cassette transporter, Abcg2, identifies cardiac SP cells in the developing and adult heart. Dev Biol 265 (2004), 262–275.
22. Wang, X., Hu, Q., Nakamura, Y., et al. The role of the sca-1+/CD31− cardiac progenitor cell population in postinfarction left ventricular remodeling. Stem Cells 24 (2006), 1779–1788.
23. Tokita, Y., Tang, X.L., Li, Q., et al. Repeated administrations of cardiac progenitor cells are markedly more effective than a single administration: a new paradigm in cell therapy. Circ Res 119 (2016), 635–651.
24. Hare, J.M., DiFede, D.L., Castellanos, A.M., et al. Randomized comparison of allogeneic versus autologous mesenchymal stem cells for nonischemic dilated cardiomyopathy: POSEIDON-DCM Trial. J Am Coll Cardiol 69 (2017), 526–537.
25. Karantalis, V., Suncion-Loescher, V.Y., Bagno, L., et al. Synergistic effects of combined cell therapy for chronic ischemic cardiomyopathy. J Am Coll Cardiol 66 (2015), 1990–1999.
26. Zeng, L., Hu, Q., Wang, X., et al. Bioenergetic and functional consequences of bone marrow-derived multipotent progenitor cell transplantation in hearts with postinfarction left ventricular remodeling. Circulation 115 (2007), 1866–1875.
27. Guo, Y., Wysoczynski, M., Nong, Y., et al. Repeated doses of cardiac mesenchymal cells are therapeutically superior to a single dose in mice with old myocardial infarction. Basic Res Cardiol, 112, 2017, 18.
28. Ban, K., Park, H.J., Kim, S., et al. Cell therapy with embryonic stem cell-derived cardiomyocytes encapsulated in injectable nanomatrix gel enhances cell engraftment and promotes cardiac repair. ACS Nano 8 (2014), 10815–10825.
29. Segers, V.F., Lee, R.T., Biomaterials to enhance stem cell function in the heart. Circ Res 109 (2011), 910–922.
30. Vunjak-Novakovic, G., Lui, K.O., Tandon, N., Chien, K.R., Bioengineering heart muscle: a paradigm for regenerative medicine. Annu Rev Biomed Eng 13 (2011), 245–267.
31. Zhao, T., Zhang, Z.N., Rong, Z., Xu, Y., Immunogenicity of induced pluripotent stem cells. Nature 474 (2011), 212–215.
32. Zhao, T., Zhang, Z.N., Westenskow, P.D., et al. Humanized mice reveal differential immunogenicity of cells derived from autologous induced pluripotent stem cells. Cell Stem Cell 17 (2015), 353–359.
33. Araki, R., Uda, M., Hoki, Y., et al. Negligible immunogenicity of terminally differentiated cells derived from induced pluripotent or embryonic stem cells. Nature 494 (2013), 100–104.
34. Guha, P., Morgan, J.W., Mostoslavsky, G., Rodrigues, N.P., Boyd, A.S., Lack of immune response to differentiated cells derived from syngeneic induced pluripotent stem cells. Cell Stem Cell 12 (2013), 407–412.
35. Abrahimi, P., Chang, W.G., Kluger, M.S., et al. Efficient gene disruption in cultured primary human endothelial cells by CRISPR/Cas9. Circ Res 117 (2015), 121–128.
36. Shiao, S.L., Kirkiles-Smith, N.C., Shepherd, B.R., McNiff, J.M., Carr, E.J., Pober, J.S., Human effector memory CD4+ T cells directly recognize allogeneic endothelial cells in vitro and in vivo. J Immunol 179 (2007), 4397–4404.
37. Hong, K.U., Guo, Y., Li, Q.H., et al. c-kit+ cardiac stem cells alleviate post-myocardial infarction left ventricular dysfunction despite poor engraftment and negligible retention in the recipient heart. PLoS One, 9, 2014, e96725.
38. Malliaras, K., Li, T.S., Luthringer, D., et al. Safety and efficacy of allogeneic cell therapy in infarcted rats transplanted with mismatched cardiosphere-derived cells. Circulation 125 (2012), 100–112.
39. Sanganalmath, S.K., Bolli, R., Cell therapy for heart failure: a comprehensive overview of experimental and clinical studies, current challenges, and future directions. Circ Res 113 (2013), 810–834.
40. Ismahil, M.A., Hamid, T., Bansal, S.S., Patel, B., Kingery, J.R., Prabhu, S.D., Remodeling of the mononuclear phagocyte network underlies chronic inflammation and disease progression in heart failure: critical importance of the cardiosplenic axis. Circ Res 114 (2014), 266–282.
41. Nevers, T., Salvador, A.M., Grodecki-Pena, A., et al. Left ventricular T-cell recruitment contributes to the pathogenesis of heart failure. Circ Heart Fail 8 (2015), 776–787.
42. Prabhu, S.D., Frangogiannis, N.G., The biological basis for cardiac repair after myocardial infarction: from inflammation to fibrosis. Circ Res 119 (2016), 91–112.
43. Sager, H.B., Hulsmans, M., Lavine, K.J., et al. Proliferation and recruitment contribute to myocardial macrophage expansion in chronic heart failure. Circ Res 119 (2016), 853–864.
44. Hamid, T., Xu, Y., Ismahil, M.A., et al. TNF receptor signaling inhibits cardiomyogenic differentiation of cardiac stem cells and promotes a neuroadrenergic-like fate. Am J Physiol Heart Circ Physiol 311 (2016), H1189–H1201.
45. Chong, J.J., Yang, X., Don, C.W., et al. Human embryonic-stem-cell-derived cardiomyocytes regenerate non-human primate hearts. Nature 510 (2014), 273–277.
46. Shiba, Y., Gomibuchi, T., Seto, T., et al. Allogeneic transplantation of iPS cell-derived cardiomyocytes regenerates primate hearts. Nature 538 (2016), 388–391.
47. Weiss, J.N., Qu, Z., Chen, P.S., et al. The dynamics of cardiac fibrillation. Circulation 112 (2005), 1232–1240.
48. Fontes, M.S., van Veen, T.A., de Bakker, J.M., van Rijen, H.V., Functional consequences of abnormal Cx43 expression in the heart. Biochim Biophys Acta 1818 (2012), 2020–2029.
49. Davis, L.M., Rodefeld, M.E., Green, K., Beyer, E.C., Saffitz, J.E., Gap junction protein phenotypes of the human heart and conduction system. J Cardiovasc Electrophysiol 6 (1995), 813–822.
50. Dupont, E., Matsushita, T., Kaba, R.A., et al. Altered connexin expression in human congestive heart failure. J Mol Cell Cardiol 33 (2001), 359–371.
51. Kostin, S., Rieger, M., Dammer, S., et al. Gap junction remodeling and altered connexin43 expression in the failing human heart. Mol Cell Biochem 242 (2003), 135–144.
52. Roell, W., Lewalter, T., Sasse, P., et al. Engraftment of connexin 43-expressing cells prevents post-infarct arrhythmia. Nature 450 (2007), 819–824.
53. Gerbin, K.A., Yang, X., Murry, C.E., Coulombe, K.L., Enhanced electrical integration of engineered human myocardium via intramyocardial versus epicardial delivery in infarcted rat hearts. PLoS One, 10, 2015, e0131446.
54. Xiong, Q., Ye, L., Zhang, P., et al. Bioenergetic and functional consequences of cellular therapy: activation of endogenous cardiovascular progenitor cells. Circ Res 111 (2012), 455–468.
55. Xiong, Q., Ye, L., Zhang, P., et al. Functional consequences of human induced pluripotent stem cell therapy: myocardial ATP turnover rate in the in vivo swine heart with postinfarction remodeling. Circulation 127 (2013), 997–1008.
56. Bolognese, L., Neskovic, A.N., Parodi, G., et al. Left ventricular remodeling after primary coronary angioplasty: patterns of left ventricular dilation and long-term prognostic implications. Circulation 106 (2002), 2351–2357.
57. Hu, Q., Wang, X., Lee, J., et al. Profound bioenergetic abnormalities in peri-infarct myocardial regions. Am J Physiol Heart Circ Physiol 291 (2006), H648–H657.
58. Feygin, J., Mansoor, A., Eckman, P., Swingen, C., Zhang, J., Functional and bioenergetic modulations in the infarct border zone following autologous mesenchymal stem cell transplantation. Am J Physiol Heart Circ Physiol 293 (2007), H1772–H1780.
59. Kobayashi, T., Yamaguchi, T., Hamanaka, S., et al. Generation of rat pancreas in mouse by interspecific blastocyst injection of pluripotent stem cells. Cell 142 (2010), 787–799.
60. Usui, J., Kobayashi, T., Yamaguchi, T., Knisely, A.S., Nishinakamura, R., Nakauchi, H., Generation of kidney from pluripotent stem cells via blastocyst complementation. Am J Pathol 180 (2012), 2417–2426.
61. Bort, R., Signore, M., Tremblay, K., Martinez Barbera, J.P., Zaret, K.S., Hex homeobox gene controls the transition of the endoderm to a pseudostratified, cell emergent epithelium for liver bud development. Dev Biol 290 (2006), 44–56.
62. Matsunari, H., Nagashima, H., Watanabe, M., et al. Blastocyst complementation generates exogenic pancreas in vivo in apancreatic cloned pigs. Proc Natl Acad Sci U S A 110 (2013), 4557–4562.
63. Porrello, E., Mahmoud, A., Simpson, E., et al. Transient regenerative potential of the neonatal mouse heart. Science 331 (2011), 1078–1080.
64. Bergmann, O., Bhardwaj, R., Bernard, S., et al. Evidence for cardiomyocyte renewal in humans. Science 324 (2009), 98–102.
65. van Berlo, J.H., Kanisicak, O., Maillet, M., et al. c-kit+ cells minimally contribute cardiomyocytes to the heart. Nature 509 (2014), 337–341.
66. van Berlo, J.H., Molkentin, J.D., Most of the dust has settled: cKit+ progenitor cells are an irrelevant source of cardiac myocytes in vivo. Circ Res 118 (2016), 17–19.
67. Hatzistergos, K.E., Takeuchi, L.M., Saur, D., et al. cKit+ cardiac progenitors of neural crest origin. Proc Natl Acad Sci U S A 112 (2015), 13051–13056.
68. Mohamed, T.M., Stone, N.R., Berry, E.C., et al. Chemical enhancement of in vitro and in vivo direct cardiac reprogramming. Circulation 135 (2017), 978–995.
69. Nam, Y.J., Song, K., Olson, E.N., Heart repair by cardiac reprogramming. Nat Med 19 (2013), 413–415.
70. Srivastava, D., Yu, P., Recent advances in direct cardiac reprogramming. Curr Opin Genet Dev 34 (2015), 77–81.
71. Kanisicak, O., Khalil, H., Ivey, M.J., et al. Genetic lineage tracing defines myofibroblast origin and function in the injured heart. Nat Commun, 7, 2016, 12260.
72. Moore-Morris, T., Cattaneo, P., Puceat, M., Evans, S.M., Origins of cardiac fibroblasts. J Mol Cell Cardiol 91 (2016), 1–5.
73. Li, Y., Dal-Pra, S., Mirotsou, M., et al. Tissue-engineered 3-dimensional (3D) microenvironment enhances the direct reprogramming of fibroblasts into cardiomyocytes by microRNAs. Sci Rep, 6, 2016, 38815.
74. Sia, J., Yu, P., Srivastava, D., Li, S., Effect of biophysical cues on reprogramming to cardiomyocytes. Biomaterials 103 (2016), 1–11.
75. Bursac, N., Kirkton, R.D., McSpadden, L.C., Liau, B., Characterizing functional stem cell-cardiomyocyte interactions. Regen Med 5 (2010), 87–105.
76. Makkar, R.R., Smith, R.R., Cheng, K., et al. Intracoronary cardiosphere-derived cells for heart regeneration after myocardial infarction (CADUCEUS): a prospective, randomised phase 1 trial. Lancet 379 (2012), 895–904.
77. A futile cycle in cell therapy. Nat Biotechnol, 35, 2017, 291.
78. Ishigami, S., Ohtsuki, S., Tarui, S., et al. Intracoronary autologous cardiac progenitor cell transfer in patients with hypoplastic left heart syndrome: the TICAP prospective phase 1 controlled trial. Circ Res 116 (2015), 653–664.
79. Tarui, S., Ishigami, S., Ousaka, D., et al. Transcoronary infusion of cardiac progenitor cells in hypoplastic left heart syndrome: three-year follow-up of the Transcoronary Infusion of Cardiac Progenitor Cells in Patients With Single-Ventricle Physiology (TICAP) trial. J Thorac Cardiovasc Surg 150 (2015), 1198–1207 1208.e1–2.
80. Ishigami, S., Ohtsuki, S., Eitoku, T., et al. Intracoronary cardiac progenitor cells in single ventricle physiology: the PERSEUS (Cardiac Progenitor Cell Infusion to Treat Univentricular Heart Disease) Randomized Phase 2 Trial. Circ Res 120 (2017), 1162–1173.
81. Choudhury, T., Mozid, A., Hamshere, S., et al. An exploratory randomized control study of combination cytokine and adult autologous bone marrow progenitor cell administration in patients with ischaemic cardiomyopathy: the REGENERATE-IHD clinical trial. Eur J Heart Fail 19 (2017), 138–147.
82. Bartunek, J., Terzic, A., Davison, B.A., et al. Cardiopoietic cell therapy for advanced ischaemic heart failure: results at 39 weeks of the prospective, randomized, double blind, sham-controlled CHART-1 clinical trial. Eur Heart J 38 (2017), 648–660.
83. Butler, J., Epstein, S.E., Greene, S.J., et al. Intravenous allogeneic mesenchymal stem cells for nonischemic cardiomyopathy: safety and efficacy results of a phase II-A randomized trial. Circ Res 120 (2017), 332–340.
84. Wojakowski, W., Jadczyk, T., Michalewska-Wludarczyk, A., et al. Effects of transendocardial delivery of bone marrow-derived CD133+ cells on left ventricle perfusion and function in patients with refractory angina: final results of randomized, double-blinded, placebo-controlled REGENT-VSEL Trial. Circ Res 120 (2017), 670–680.
85. Miyagawa, S., Domae, K., Yoshikawa, Y., et al. Phase I clinical trial of autologous stem cell-sheet transplantation therapy for treating cardiomyopathy. J Am Heart Assoc, 6, 2017, e003918.
86. Wollert, K.C., Meyer, G.P., Müller-Ehmsen, J., et al. Intracoronary autologous bone marrow cell transfer after myocardial infarction: the BOOST-2 randomised placebo-controlled clinical trial. Eur Heart J, 2017 Apr 19 [E-pub ahead of print].